Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
MNKD logo MNKD
Upturn stock ratingUpturn stock rating
MNKD logo

MannKind Corp (MNKD)

Upturn stock ratingUpturn stock rating
$5.1
Delayed price
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

03/27/2025: MNKD (4-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

ratingratingratingratingrating

Above Average Performance

These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.

AI Based Fundamental Rating

ratingratingratingratingrating

Moderate Performance

These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.

Analysis of Past Performance

Type Stock
Historic Profit -0.87%
Avg. Invested days 31
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 3.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 03/27/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 1.56B USD
Price to earnings Ratio 70.62
1Y Target Price 10
Price to earnings Ratio 70.62
1Y Target Price 10
Volume (30-day avg) 2121613
Beta 1.28
52 Weeks Range 3.97 - 7.63
Updated Date 03/30/2025
52 Weeks Range 3.97 - 7.63
Updated Date 03/30/2025
Dividends yield (FY) -
Basic EPS (TTM) 0.08

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin 8.07%
Operating Margin (TTM) 21.71%

Management Effectiveness

Return on Assets (TTM) 9.12%
Return on Equity (TTM) -

Valuation

Trailing PE 70.62
Forward PE 29.59
Enterprise Value 1377504460
Price to Sales(TTM) 5.35
Enterprise Value 1377504460
Price to Sales(TTM) 5.35
Enterprise Value to Revenue 4.82
Enterprise Value to EBITDA 17.77
Shares Outstanding 275777984
Shares Floating 270675806
Shares Outstanding 275777984
Shares Floating 270675806
Percent Insiders 2.06
Percent Institutions 61.47

Analyst Ratings

Rating 4.8
Target Price 9.8
Buy 1
Strong Buy 4
Buy 1
Strong Buy 4
Hold -
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

MannKind Corp

stock logo

Company Overview

History and Background

MannKind Corp was founded in 1991. It's a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases. Early struggles led to restructuring, but recent focus on Afrezza and other pipeline drugs has improved its outlook.

Core Business Areas

  • Inhaled Therapeutics: Development and commercialization of inhaled therapeutic products, primarily focusing on Afrezza for diabetes.
  • Orphan Lung Diseases: Research and development of therapies for rare pulmonary diseases.

Leadership and Structure

Michael Castagna serves as the Chief Executive Officer. The company operates with a functional organizational structure, emphasizing research, development, and commercial operations.

Top Products and Market Share

Key Offerings

  • Afrezza: Afrezza is an inhaled insulin product used to control blood sugar in adults with diabetes. Market share information is difficult to pinpoint precisely, but MannKind controls a small fraction of the total insulin market, but a larger share of rapid acting insulins. Competitors include Novo Nordisk (NovoLog), Eli Lilly (Humalog, Lyumjev), and Sanofi (Apidra). Afrezza generated a significant portion of MannKind's revenue and growing.
  • Tyvaso DPI: MannKind partnered with United Therapeutics (UTHR) to manufacture and commercialize Tyvaso DPI, an inhaled dry powder formulation of treprostinil for pulmonary hypertension. Mannkind receives a percentage of the revenue from UTHR.

Market Dynamics

Industry Overview

The pharmaceutical industry, specifically the diabetes and pulmonary disease segments, is characterized by intense competition, strict regulatory requirements, and continuous innovation.

Positioning

MannKind is a niche player focusing on inhaled therapies. Its competitive advantage lies in its Technosphere technology, which allows for rapid insulin absorption. This positions them well within the niche rapid acting insulin market. Their partnership with United Therapeutics provides them with increased income through revenue and manufacturing.

Total Addressable Market (TAM)

The total addressable market for diabetes treatments and pulmonary hypertension therapies is substantial, estimated in the tens of billions of dollars. MannKind, focuses on a specific segment, namely rapid-acting insulin for diabetes and inhaled therapies for pulmonary diseases, is well-positioned to capture a segment of this market.

Upturn SWOT Analysis

Strengths

  • Technosphere technology (rapid drug absorption)
  • Partnership with United Therapeutics (Tyvaso DPI)
  • Focus on niche markets (inhaled therapies)
  • Strong IP portfolio

Weaknesses

  • History of financial instability
  • Limited sales and marketing infrastructure (compared to larger competitors)
  • Dependence on a few key products
  • Smaller market share within the large insulin market

Opportunities

  • Expansion into new therapeutic areas
  • Strategic partnerships and collaborations
  • Increasing adoption of inhaled therapies
  • Growing prevalence of diabetes and pulmonary diseases

Threats

  • Competition from established pharmaceutical companies
  • Regulatory hurdles and clinical trial risks
  • Patent expirations
  • Pricing pressure from insurers and PBMs

Competitors and Market Share

Key Competitors

  • NVO
  • LLY
  • SNY

Competitive Landscape

MannKind faces intense competition from established players in the insulin market. Its inhaled insulin offers a unique value proposition, but it must overcome challenges in market adoption and pricing.

Major Acquisitions

Growth Trajectory and Initiatives

Historical Growth: Revenue growth has accelerated in recent years due to increased Afrezza sales and royalty income from Tyvaso DPI.

Future Projections: Analysts expect continued revenue growth driven by Afrezza adoption and pipeline development. Monitor the market and sales of Afrezza, along with new indication of treatments for orphan lung diseases.

Recent Initiatives: Focus on expanding Afrezza market reach, pursuing new clinical trials, and exploring partnerships for pipeline products.

Summary

MannKind Corp shows improving revenues and promising partnerships, particularly with the FDA approved drug Afrezza. Financial results show losses are still present but steadily decreasing. The company still needs to focus on overcoming marketing and commercial infrastructure challenges, in order to further increase adoption. Investors should continue to monitor revenue growth, cash flow, and market dynamics for the insulin rapid acting market.

Similar Companies

  • NVO
  • LLY
  • SNY
  • UTHR

Sources and Disclaimers

Data Sources:

  • Company SEC Filings
  • Analyst Reports
  • Industry Publications

Disclaimers:

The information provided is for informational purposes only and should not be considered financial advice. Market share data is estimated and may not be precise. Invest at your own risk.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About MannKind Corp

Exchange NASDAQ
Headquaters Danbury, CT, United States
IPO Launch date 2004-07-28
CEO & Director Dr. Michael E. Castagna Pharm.D.
Sector Healthcare
Industry Biotechnology
Full time employees 403
Full time employees 403

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of therapeutic products and services for endocrine and orphan lung diseases in the United States. It offers Afrezza Inhalation Powder, an inhaled insulin used to improve glycemic control in adults with diabetes; the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults; and Tyvaso DPI for the treatment of pulmonary arterial hypertension and pulmonary hypertension. The company's product pipeline includes MNKD-101, a nebulized formulation of clofazimine, which is in Phase 3 study, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, which is in phase 1 clinical study, for the treatment of idiopathic pulmonary fibrosis (IPF); MNKD-301, which is in preclinical stage, for cystic fibrosis; and Pediatric Afrezza, which is in phase 3 clinical trial for the treatment of diabetes mellitus. It has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India; and co-promotion agreement with Amphastar for marketing of Baqsimi (glucagon) nasal powder. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​